NCT05607589View on ClinicalTrials.gov

The Safety, Tolerability, PK, and PD of DWP213388 After SAD and MAD Administration in Healthy Adult Subjects

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2022

Primary Completion Date

February 20, 2024

Study Completion Date

March 8, 2024

Conditions
Healthy
Interventions
DRUG

DWP213388

immunosuppressant

OTHER

Placebo

Placebo

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT05607589 - The Safety, Tolerability, PK, and PD of DWP213388 After SAD and MAD Administration in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter